Corient Private Wealth LLC purchased a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,492 shares of the company’s stock, valued at approximately $316,000. Corient Private Wealth LLC owned 0.14% of Inhibrx as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in INBX. PNC Financial Services Group Inc. bought a new stake in shares of Inhibrx during the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. acquired a new stake in Inhibrx during the fourth quarter worth $47,000. New York State Common Retirement Fund bought a new stake in Inhibrx in the 4th quarter valued at $53,000. Exchange Traded Concepts LLC acquired a new position in shares of Inhibrx in the 4th quarter valued at $148,000. Finally, Rhumbline Advisers acquired a new position in shares of Inhibrx in the 4th quarter valued at $228,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Inhibrx Trading Down 1.4 %
INBX stock opened at $14.12 on Monday. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $35.42. The business’s 50 day moving average is $13.36 and its 200-day moving average is $14.60.
Inhibrx (NASDAQ:INBX – Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. On average, analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current year.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Further Reading
- Five stocks we like better than Inhibrx
- What is a Stock Market Index and How Do You Use Them?
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- What is the MACD Indicator and How to Use it in Your Trading
- MarketBeat Week in Review – 03/24 – 03/28
- The 3 Best Retail Stocks to Shop for in August
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Want to see what other hedge funds are holding INBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inhibrx, Inc. (NASDAQ:INBX – Free Report).
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
